1. Scrip
  2. >>Business
  3. >>Deals

Novartis Doubles Up In Optogenetics With Arctos Buy

Complements Acquisition Of Vedere Last Year

 
• By Kevin Grogan

The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.

Close-up of blue eye. High Technologies in the futuristic. : cataract
• Source: Archive

Almost a year after acquiring optogenetics specialist Vedere Bio, Inc. , Novartis AG has decided to buy another in the shape of Swiss inherited eye disease expert Arctos Medical.

Arctos is a University of Bern spin-off incubated by +ND Capital working with scientific co-founders Sonja Kleinlogel and Michiel van...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.